Cargando…

Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells

Detalles Bibliográficos
Autores principales:	Shi, Yuanfei, Xu, Yi, Xie, Wanzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2022
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311018/ https://www.ncbi.nlm.nih.gov/pubmed/37397564 http://dx.doi.org/10.1016/j.gendis.2022.07.012

Ejemplares similares

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
por: Xavier, Flávia Dias, et al.
Publicado: (2014)

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
por: ZL, Wu, et al.
Publicado: (2011)

Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma
por: Shi, Yuanfei, et al.
Publicado: (2022)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma
por: Bian, Zhouliang, et al.
Publicado: (2023)

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma
por: Tang, Jing, et al.
Publicado: (2023)

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo
por: Damm, Jesper Kofoed, et al.
Publicado: (2015)

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
por: Juskevicius, Darius, et al.
Publicado: (2017)

Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
por: Jin, Xuan, et al.
Publicado: (2012)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population
por: Levy, Débora, et al.
Publicado: (2011)

Stabilization of MYC G-quadruplex DNA by ruthenium (II) complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation
por: Sun, Yuening, et al.
Publicado: (2022)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
por: Shi, Chaowen, et al.
Publicado: (2023)

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma
por: Granau, Agnete Marie, et al.
Publicado: (2023)

Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report
por: Li, Dan, et al.
Publicado: (2023)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
por: Wei, Andrew H., et al.
Publicado: (2019)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017)

Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: a single-center study of 259 Chinese patients
por: Xu, Yi, et al.
Publicado: (2023)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
por: Jeon, Youngwoo
Publicado: (2023)

Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
por: Jeon, Min Ji, et al.
Publicado: (2023)

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
por: Lin, Ningjing, et al.
Publicado: (2013)

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
por: Hutchings, Martin, et al.
Publicado: (2021)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

A Pulmonary Large Cell Carcinoma Cell Line Expressing Neuroendocrine Cell Markers and Human Chorionic Gonadotropin α‐Subunit
por: Kasai, Kiyoshi, et al.
Publicado: (1991)

Inhibition of in vitro Tumor Cell Invasion by Transmethylation Inhibitors
por: Sbinkai, Kiyoko, et al.
Publicado: (1989)

Development and validation of platelet-to-albumin ratio as a clinical predictor for diffuse large B-cell lymphoma
por: Wang, Jinghan, et al.
Publicado: (2023)

Feedforward inhibition is randomly wired from individual granule cells onto CA3 pyramidal cells
por: Neubrandt, Máté, et al.
Publicado: (2017)

MyD88 in macrophages protects against colitis via inhibiting the activation of NLRP3 inflammasome in epithelial cells
por: Liu, Shi, et al.
Publicado: (2022)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
por: Dickinson, Michael, et al.
Publicado: (2021)

Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Petrillo, Alessandra, et al.
Publicado: (2022)

Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy
por: XIE, WANZHUO, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g22blia7jiok9sghqonggobrsm